A28 Therapeutics Announces Late-Stage Clinical Development Of Cancer-Killing AT-101 Lytic Peptide Molecule
A28 Therapeutics, a privately-held, clinical-stage biopharmaceutical company focused on the development of cancer treatments, has announced that its AT-101 lytic ...
